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Edited by Veli-Pekka LehtoAbstract Capsaicin, a major ingredient of hot pepper, is
considered to exhibit anti-inﬂammatory properties. Our previous
study demonstrated that capsaicin inhibited the production of
pro-inﬂammatory mediators through NF-jB inactivation in
LPS-stimulated macrophages. In order to further clarify the
mechanism underlying the anti-inﬂammatory action of capsaicin,
we investigated whether capsaicin alters PPARc activity, which
regulates the production of the pro-inﬂammatory cytokine
TNFa. Capsaicin signiﬁcantly inhibited the production of TNFa
by macrophages in a dose-dependent manner. Simultaneous
exposure of the cells to capsaicin and PPARc agonist troglit-
azone or RXR agonist LG100268 resulted in stronger inhibition
of TNFa production compared to the cells treated with either
capsaicin, troglitazone, or LG100268 alone. Luciferase reporter
assay revealed that capsaicin induced GAL4/PPARc chimera
and full length PPARc (PPRE) transactivations in a dose-
dependent manner. Furthermore, a speciﬁc PPARc antagonist
T0070907 abrogated the inhibitory action of capsaicin on LPS-
induced TNFa production by RAW 264.7 cells, indicating that
capsaicin acts like a ligand for PPARc. Our data demonstrate
for the ﬁrst time that the anti-inﬂammatory action of capsaicin
may be mediated by PPARc activation in LPS-stimulated RAW
264.7 cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Inﬂammation is a pivotal component of a variety of diseases
such as atherosclerosis and tumor progression. Various natu-
rally occurring phytochemicals (e.g., curcumin and ﬂavonoids)
exhibit anti-inﬂammatory activity and are considered to be
potential drug candidates against the inﬂammation-related
pathological processes [1]. Capsaicin, the major ingredient of
hot pepper, and with a structure similar to that of curcumin,
has also been shown to elicit anti-inﬂammatory properties* Corresponding author. Fax: +82-52-259-1699.
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doi:10.1016/j.febslet.2004.06.084[1,2]. Our previous study demonstrated that capsaicin inhibited
the production of pro-inﬂammatory mediators such as PGE2
and nitric oxide by nuclear transcription factor kappa B (NF-
jB) inactivation in murine peritoneal macrophages [3]. Inter-
estingly, the inhibitory action of capsaicin on the release of
pro-inﬂammatory molecules was not mediated by a vanilloid
receptor-1 (VR-1) [3], which is a speciﬁc receptor for capsaicin,
indicating the involvement of an alternative mechanism.
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor superfamily and three sub-
types have been identiﬁed (PPAR, PPARd, and PPARc).
PAPRc forms a heterodimer with retinoid X receptor (RXR)
and regulates the expression of target genes by binding to the
PPAR responsive element (PPRE) [4,5]. It is well known that
PPARc plays a pivotal role in adipogenesis and fatty acid
metabolism [6,7]. Recent studies have shown that PPARc
modulates the production of certain inﬂammatory mediators
and thus can be implicated in the pathogenesis of inﬂamma-
tory diseases. Troglitazone or pioglitazone, a synthetic ligand
for PPARc, suppresses the production of pro-inﬂammatory
cytokines such as TNFa and nitric oxide in LPS-stimulated
macrophages [8,9]. Naturally occurring compounds such as
fatty acids and the prostaglandin D2 metabolite 15-deoxy-D
12,14-prostaglandin J2 (15d-PGJ2), which are major products
of arachidonic acid metabolism, are also known to activate
PPARc and thus regulate inﬂammatory responses in macro-
phage [10,11]. The nuclear receptor RXR exerts its gene reg-
ulatory activity either as a homodimer (RXR:RXR) or
heterodimer with other nuclear receptors such as PPARs
[12,13]. The RXR ligands Ro47-5944 or LG100268 inhibited
LPS-induced nitric oxide and TNFa production in rat kupﬀer
cells through PPARc:RXR activation [8]. These results suggest
that ligands for PPARc or RXR may exhibit anti-inﬂamma-
tory properties through the activation of those transcription
factors.
Non-steroidal anti-inﬂammatory drugs such as aspirin,
which can suppress the production of pro-inﬂammatory cy-
tokines (e.g., TNFa and IL-6), are known to activate PPARc
[10,14,15]. Since target genes for PPARc include TNFa as
well as iNOS or COX-2, we hypothesized that capsaicin
might modulate the PPARc pathway. The present study
demonstrates for the ﬁrst time that capsaicin suppresses theblished by Elsevier B.V. All rights reserved.
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LPS-stimulated murine macrophages RAW 264.7. Capsaicin
may be a naturally occurring ligand for PPARc, which can be
useful therapy against inﬂammation.2. Materials and methods
2.1. Materials
Dulbecco’s modiﬁed Eagle medium (DMEM) and fetal calf serum
(FCS) were from Gibco BRL, and lipopolysaccharide (LPS) was from
Sigma. Capsaicin was purchased from TOCRIS. Troglitazone and
pioglitazone were purchased from Sankyo Co. and Takeda Chemical
Industries, respectively. T0070907 was purchased Cayman. LG100268
was synthesized by a method previously described [16]. OptEIATM
mouse TNFa kit was from PharMingen. Anti-rabbit IgG antibody and
Western blotting detection reagent (ECL) were from Amersham
Pharmacia Biotech. Anti-PPARc antibody was from ABR.
2.2. Cells culture
The murine macrophage cell line, RAW 264.7, was obtained from
Korean Cell Line Bank and CV-1 monkey kidney cells were from
American Type Culture Collection. The cells were cultured in Dul-
becco’s modiﬁed Eagle’s medium supplemented with 10% FCS and 10
mg/l penicillin-streptomycin (Gibco BRL), 2 mg/l gentamicin (Gibco
BRL) at 37 C, 5% CO2. The media were changed every 3 days and the
cells were separated via trypsinization, using trypsin/EDTA (Gibco
BRL).
2.3. Western blot analysis
RAW 264.7 macrophages were cultured in 100-mm dishes and rinsed
three times with ice-cold phosphate-buﬀered saline (PBS), lysed with
100 ll of Tris (25 mM)/EDTA (1 mM) buﬀer (pH 7.5), and then mi-
crocentrifuged at 15 000 rpm for 5 min. Protein content of extracts was
quantitated by BCA protein kit (Pierce) and stored at )80 C. Equal
amounts of protein (30 lg) were loaded and electrophoresed on a 11%
sodium dodecyl sulfate-polyacrylamide gels for electrophoresis (SDS–
PAGE) and transferred to nitrocellulose membranes (BIO-RAD). The
membrane was blocked in TBS with 5% skimmed milk for 3 h and was
treated overnight with a rabbit polyclonal anti-PPARc antibody in
TBS with 1% skimmed milk (1:1000). After washing, the membrane
was incubated for 2 h with horseradish peroxidase-conjugated anti-
rabbit IgG antibody (Amersham) in TBS with 5% skimmed milk
(1:1000). The immunoreactive protein was detected with a chemilu-
minescent system (ECL kit, Amersham).
2.4. RT-PCR analysis
Total RNA was extracted from 2 107 cells using an RNeasy kit
(Qiagen). An aliquot of 0.5 lg of RNA was used for reverse tran-
scription and was ampliﬁed using a polymerase chain reaction (PCR)
technique in a single reaction, using the Access RT-PCR system ac-
cording to the manufacturer’s instructions in a TaKaRa Thermal cy-
cler (TaKaRa, Biomedicals).
The following sets of primers were used in PCR ampliﬁcation: b-actin
(Gene Bank Accession No. X03672), forward 50-ATGAAGATCCTG-
ACCGAGCGT-30, reverse 50-AACGCAGCTCAGTAACAGTCCG-30;
VR-1 (AF029310), forward 50-GTGAGACCCCTAACCGTCATGA-
30, reverse 50-CCTT CCACAGGCCGATAGTA-30; VRL-1
(BC005415), forward 50-CAAGTACCTCACTGACTCGGCATAC-30,
reverse 50-TTCTCTACCAGcagttcacgca-30; and PPARc (U01841),
forward 50-GGAGATCTCCAGTGATATCGACCA-30, reverse 50-
ACGGCTTCTACGGATCGA AACT-30. The conditions of PCR for
the target genes were as previously described [3,17].
For semiquantitative analysis, the linearity of ampliﬁcation of VR-1
and PPARc and b-actin cDNAs was established in preliminary ex-
periments. Ampliﬁcation products obtained by PCR were electro-
phoretically separated on a 2% agarose gel. SYBR Green-stained
bands corresponding to the target genes and b-actin were photo-
graphed with a DS-34 Polaroid camera.
2.5. Measurement of TNFa
The concentration of TNFa in culture supernatants was assessed by
enzyme-linked immunosorbent assay (ELISA). The assays were con-ducted utilizing the OptEIATM Mouse TNFa kit (Pharmingen). The
sample (triplicate) was thawed, diluted properly in assay diluent, and
assayed. The absorbance of each well was read at 450 nm on a Vmax
Kinetic Microplate Reader (Molecular Devices). Cytokine was quan-
titated from standard curve using the SOFTmax curve-ﬁtting program
(Molecular Devices).
2.6. Luciferase reporter assays
PPARc luciferase assay was performed by the method previously
described [7,17]. Brieﬂy, using GAL4/PPAR chimera protein, we
transfected p4xUASg-tk-luc (a reporter plasmid) and pM-PPARc (an
expression plasmid for GAL4/PPAR-ligand binding domain chimera
protein) into CV1 cells cultured on 24-well tissue culture plates. In the
case of a PPRE system, p4xPPRE-tk-luc (0.2 lg/well) and pDEST-
hPPARc (full-length PPAR expression vectors) (0.2 lg/well) were also
transfected into CV1 cells cultured on 24-well tissue culture plates. The
transfection was performed by LipofectAMINE (Invitrogen, USA)
using the manufacturer’s protocol. Twenty four hours after transfec-
tion, the transfected cells were cultured in medium containing each
compound for an additional 24 h. Luciferase assays were performed
using the dual luciferase system according to the manufacturer’s
protocol.
2.7. Cell viability
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide) assay was used to assess the viability of RAW 264.7 cell after
treatment [3]. Cell viabilities were determined colorimetrically by using
an automated 96-well plate reader (Molecular Devices) and SOFTmax
software to measure absorbance at 570 nm.
2.8. Statistical analysis
The data were presented as meansS.E.M. and were statistically
analyzed using ANOVA and the unpaired t-test. Diﬀerences were
considered signiﬁcant when P was <0.05.3. Results
3.1. Expression of VR-1, VRL-1, or PPARc in murine
macrophages, RAW 264.7
We examined whether VR-1 or VR-1-like protein (VRL-1)
mRNA was expressed in RAW 264.7 by RT-PCR analysis.
The speciﬁc expression of RT-PCR products of VR-1 mRNA
in RAW 264.7 was not detected, although the products of
VR-1 were clearly expressed in rat and mouse brain (positive
controls) (Fig. 1A). VRL-1 (non-sensitive to capsaicin) mRNA
was expressed (Fig. 1B). It has been shown that VR-1 is mainly
localized at the plasma membrane in VR-1 transfected cells [2].
We conﬁrmed that VR-1 protein was also not expressed in
RAW 264.7 cells (Fig. 1C), while it was detected in human
keratinocyte (positive control). The expression pattern was
similar to peritoneal macrophage observed in our previous
study [3]. We also examined the expression of PPARc mRNA
and the protein in RAW 264.7 and 3T3-L1 (positive control)
by RT-PCR and Western blot analysis. We found that RAW
264.7 macrophage highly expressed PPARc mRNA and pro-
tein (Fig. 1D and E).
3.2. Eﬀects of capsaicin and PPARc agonist on LPS-induced
TNFa production by murine macrophages, RAW 264.7
To examine whether capsaicin inhibits TNFa production,
murine macrophages (RAW 264.7) were stimulated with LPS
in the presence or absence of capsaicin. Either capsaicin or
PPARc agonists at the concentrations used in this study did
not aﬀect cell viability (data not shown). Capsaicin signiﬁ-
cantly inhibited LPS-induced TNFa production by RAW
264.7 cells in a dose-dependent manner (Fig. 2). PPARc
Fig. 1. Expression of VR-1 or PPARc in murine macrophages, RAW 264.7. The expression of VR-1 (A), VRL-1 (B), and PPARc (D) mRNA was
determined by RT-PCR. Total RNA was extracted from murine macrophages RAW 264.7 used for RT-PCR analysis as described in Section 2. R,
rat; M, mouse. The expression of VR-1 (C) and PPARc (E) protein in RAW 264.7 was determined by Western blot analysis. Total protein extracts
were prepared from cultured RAW 264.7 or 3T3-L1 cells. Protein extracts (30 lg) were analyzed by 11% SDS–PAGE and Western blotting with
antibody against PPARc protein. Results are representatives of two separate experiments.
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Fig. 2. Eﬀect of capsaicin and PPARc speciﬁc agonist on LPS-stimu-
lated TNFa production by RAW 264.7 cells. Murine macrophages,
RAW 264.7 (1 106/well), were pretreated with various concentrations
of capsaicin or PPARc agonist (troglitazone) for 4 h at 37 C. The cells
were stimulated with LPS (100 ng/ml) and incubated for 16 h. The
levels of TNFa in the culture medium were measured by ELISA. The
values are means±S.E.M. of three separate experiments. (A) Capsai-
cin and/or troglitazone treatment. *Signiﬁcantly diﬀerent from the
levels of TNFa production in RAW 264.7 cells treated with LPS alone,
P < 0:01.
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Fig. 3. Eﬀect of capsaicin and RXR speciﬁc agonist on LPS-stimulated
TNFa production by murine macrophages, RAW 264.7. Murine
macrophages, RAW 264.7 (1 106/well), were pretreated with various
concentrations of capsaicin or RXR agonist (LG100268), for 4 h at 37
C. The cells were stimulated with LPS (100 ng/ml) and incubated for
16 h. The levels of TNFa in the culture medium were measured by
ELISA. The values are meansS.E.M. of three separate experiments.
*Signiﬁcantly diﬀerent from the levels of TNFa production in RAW
264.7 cells treated with LPS alone, P < 0:01.
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macrophage, as previously reported [8]. Capsaicin at a con-
centration of 10, 30, and 50 lM inhibited TNFa production by
36%, 42%, and 59% in LPS-stimulated RAW 264.7 cells, while
troglitazone at a concentration of 2, 5, and 10 lM inhibited
LPS-stimulated TNFa production by 15%, 48%, and 54%,
respectively. Simultaneous treatment with both capsaicin (30
lM) and troglitazone (5 lM) resulted in greater inhibition
(83%) on TNFa production when it is compared to the single
treatment of capsaicin (42%) or troglitazone (48%) alone at the
same concentration (Fig. 2). Combined treatment with both
capsaicin and pioglitazone also resulted in greater inhibition
on LPS-induced TNFa production when it was compared to
either capsaicin or pioglitazone alone (data not shown).3.3. Eﬀects of capsaicin and RXR agonist on LPS-induced
TNFa production by murine macrophages, RAW 264.7
The nuclear receptor PPARc can exert its transcriptional
activity as a heterodimer with RXR or heterodimer with other
nuclear receptors [11]. To examine whether capsaicin can act as
a ligand for PPARc, we investigated the eﬀect of capsaicin on
LPS-stimulated TNFa by RAW 264.7 in the presence of the
synthetic RXR agonist. RXR agonist (LG100268) at a con-
centration of 2 nM did not aﬀect LPS-induced TNFa and
LG100268 at a concentration of 5 nM resulted in an inhibition
of TNFa production by 12% in RAW 264.7 cells (Fig. 3).
However, simultaneous treatment with both 30 lM capsaicin
and 2 nM LG100268 markedly inhibited the LPS-induced
TNFa production by 94%.
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Fig. 4. Eﬀect of capsaicin on the activation of PPARc or PPRE
binding in luciferase ligand assays. CV-1 cells are transfected with
(A) p4xUASg-tk-luc (a reporter plasmid) and pM-PPARc (an ex-
pression plasmid for GAL4/PPAR-ligand binding domain chimera
protein), (B) p4xPPRE-tk-luc and pDEST-hPPARc (full-length PPAR
expression vectors) in the presence of LipofectAMINE. Twenty four
hours after transfection, the transfected cells were cultured in medium
containing capsaicin for additional 24 h. The activity of a vehicle
control was set at 100% and the relative luciferase activities were
presented as fold induction to that of the vehicle control. The values
are means S.E.M. of four separate experiments. *P < 0:05 compared
with vehicle controls.
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Fig. 5. Eﬀect of PPARc antagonist on the inhibitory action of capsaicin
on LPS-stimulated TNFa production by murine macrophages, RAW
264.7. Murine macrophages, RAW 264.7 (1 106/well) were pretreated
with various concentrations of capsaicin or PPARc antagonist
(T0070907), for 4 h at 37 C. The cells were stimulated with LPS (100 ng/
ml) and incubated for 16 h. The levels of TNFa in the culture medium
were measured by ELISA. Each bar represents the meanS.E.M. of
triplicate determinations *Signiﬁcantly diﬀerent from the levels of
TNFa production in RAW 264.7 cells treated with capsaicin alone,
P < 0:01.
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The eﬀect of capsaicin on TNFa release by RAW 264.7 in-
dicated that capsaicin might have potential acting as a PPARc
ligand. To support the evidence that capsaicin can alter ac-
tivity of PPARc, we performed luciferase ligand assays using
the PPARc/GAL4 chimera system for capsaicin. Interestingly,
we found that capsaicin activated GAL4/PPARc chimera
transactivations in a dose-dependent manner (Fig. 4A).
Moreover, we examined whether capsaicin activated full length
PPARc (PPRE) using p4xPPRE-tk-luciferase reporter plas-
mid. As shown in Fig. 4B, capsaicin activated PPRE-depen-
dent luciferase activities in a dose-dependent manner in human
PPARc-transfected CV1 cells. Our data clearly indicate that
capsaicin can act as a PPARc ligand.
3.5. Capsaicin action is abrogated by a speciﬁc PPARc
antagonist
To obtain direct evidence on the PPARc ligand action of
capsaicin, we tested whether a PPARc antagonist blocked
capsaicin action on TNFa release by LPS-stimulated macro-
phage. A speciﬁc PPARc antagonist, T0070907, abrogated the
inhibitory action of capsaicin on LPS-stimulated TNFa pro-
duction in Raw 264.7 cells. The result indicates that capsaicin
acts as PPARc ligand (Fig. 5).4. Discussion
This study demonstrated that capsaicin suppresses pro-in-
ﬂammatory cytokine TNFa production in LPS-stimulated
RAW 264.7 cells and that the inhibitory action of capsaicin
was associated with PPARc activation. Capsaicin may be a
naturally occurring ligand for PPARc, which could be useful
for ameliorating inﬂammatory diseases.
Anti-inﬂammatory activity of capsaicin in non-neuronal
cells is known to occur via vanilloid receptors-independent
manner [3,18], indicating that capsaicin action is associated
with an alternative signaling pathway. Studies have shown
that PPARc ligand exhibits anti-inﬂammatory properties
[8,9]. Troglitazone or pioglitazone, a synthetic ligand for
PPARc, is known to inhibit LPS-induced TNFa production
in rat kupﬀer cells [8] and PMA-induced TNFa production in
monocytes [9]. In the present study, we found that RAW
264.7 did not express VR-1, but expressed PPARc. Indeed,
the production of TNFa by LPS-stimulated RAW 264.7
macrophages was inhibited by capsaicin treatment. The re-
sults suggest that the inhibitory action of capsaicin on the
TNFa release may be associated with PPARc, but not VR-1
pathway in RAW 264.7 cells. We also found that simulta-
neous treatment of capsaicin and the PPARc agonist, trog-
litazone or pioglitazone, resulted in greater inhibitory eﬀect
on TNFa production compared to their single treatment. The
result indicates that capsaicin has a potential to exhibit an
agonistic activity for PPARc activation in a similar manner to
troglitazone or pioglitazone.
Recent studies have shown that inﬂammatory cytokine (e.g.,
TNFa and IL-1) treatment suppresses the expression of target
genes for PPARc through NFB-mediated inhibition of the
binding of PPRE by PPARc/RXRa heterodimers [19]. Ruan
et al. [20] have demonstrated that troglitazone inhibits
transcriptional regulatory function of NF-jB, leading to
270 J.-Y. Park et al. / FEBS Letters 572 (2004) 266–270antagonize TNFa-induced adipocyte gene expression, sug-
gesting that PPAR activation may modulate NF-jB pathway.
Previously, we revealed that capsaicin inhibited NF-jB acti-
vation in LPS-stimulated murine peritoneal macrophages,
leading to the reduction of pro-inﬂammatory mediators (e.g.,
COX-2, PGE2, iNOS, and NO) [3]. Combining this and our
ﬁndings in the present study, the inhibition of NF-jB activa-
tion by capsaicin may be associated with PPARc activation.
When we examined whether capsaicin could be a ligand for
PPARc using luciferase report assay, we found that capsaicin
induced GAL4/PPARc chimera and full length PPARc
(PPRE) transactivations in a dose-dependent manner. Fur-
thermore, using a PPARc antagonistic ligand T0070907, we
demonstrated that PPARc antagonist abrogated the inhibitory
action of capsaicin on TNFa production in RAW 264.7 cells.
These results clearly reveal that capsaicin can act as a ligand
for PPARc, indicating that the anti-inﬂammatory action of
capsaicin is mediated by PPARc pathway.
Interestingly, the RXR agonist LG100268 inhibited LPS-
induced TNFa production, and combined treatment with
capsaicin markedly enhanced the inhibitory eﬀect on TNFa
production. RXR forms heterodimers with PPARc, and this
type of heterodimer can be activated by the binding of the
respective ligand to either RXR or PPARc. Studies have
shown the enhanced or synergistic eﬀects of PPARc ligands in
combination with RXR ligands, resulting in either activation
or suppression of a speciﬁc gene [21–24]. Recently, Berger et al.
[8,25] have revealed that PPARc forms a functional heterodi-
mer with RXR and occupancy of both ligand binding domains
is required for maximal receptor activity. Therefore, the en-
hanced inhibitory eﬀect of capsaicin with LG100268 observed
in our study supports the idea that capsaicin acts as a PPARc
ligand in LPS-stimulated RAW 264.7 macrophages.
In conclusion, capsaicin inhibited the production of pro-in-
ﬂammatory cytokine TNFa by LPS-stimulated RAW 264.7 in a
dose-dependent manner. Simultaneous exposure of the cells to
capsaicin and PPARc agonist troglitazone or RXR agonist
LG100268 resulted in stronger inhibition compared to the cells
treated with either capsaicin, troglitazone, or LG100268 alone.
Luciferase assay revealed that capsaicin induced GAL4/PPARc
chimera and full length PPARc (PPRE) transactivations in a
dose-dependent manner. Moreover, PPARc antagonist
T0070907 abrogated the inhibitory action of capsaicin on LPS-
induced TNFa production byRAW264.7 cells. Taken together,
our data indicate that the inhibitory action of capsaicin against
TNFa production in LPS-stimulated RAW 264.7 cells is medi-
ated by PPARc activation. The PPARc ligand-like action of
capsaicinmay be important to understand a novelmechanism in
the anti-inﬂammatory action of capsaicin.
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